Biopharma Insights - page 2

Is the Future of AI Drug Discovery Hybrid?

Some field notes from the cutting edge of modern bioinformatics (CoFold Summit and Free Energy Workshop, both held recently in Barcelona, Spain). ALSO: several companies to watch in techbio space. …

Continue ›››

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One, a Packaged ADME Service for Early Discovery

Ginkgo Bioworks' (NYSE: DNA) Datapoints arm, Tangible Scientific, and Inductive Bio today launched ADME-One, a single-SKU service that combines a Tier 1 ADME panel, AI-driven human pharmacokinetic projection, and compound …

Continue ›››

Is “Rescuing Failed Drugs with AI” a Category Now?

Inside the growing bet that AI can find the patients pharma's failed trials missed... In April, a Toronto-based startup called Biossil came out of stealth with a total of $70 …

Continue ›››

AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.

In a recent large-scale code modernization initiative, a team used generative AI to convert a clinical data standards library from one programming language to another. Nearly 80% of the templates …

Continue ›››

From Biohacking to Healthcare: The Growing Pains of the Longevity Industry

Part I: A tour of the therapeutic strategies targeting the hallmarks of aging—from cellular reprogramming to senolytics, mTOR inhibitors, and immune rejuvenation.

Continue ›››

Everyone is Launching AI Agents. What's Being Deployed?

A deep dive on the next cycle of biopharma's AI buildout Last year's "growing buzz around AI agents" that we surveyed has since grown into a full avalanche of infrastructure …

Continue ›››

Simulating the Control Arm: Virtual Patients at the Trial Bottleneck

Digital twins promise smaller, faster trials, and the regulatory scaffolding is forming. But there’s still a validation gap. Clinical trials remain the most expensive bottleneck in drug development. And although …

Continue ›››

Unlocking the Full Potential of Precision Medicine: Why Companion Diagnostics Must Start at Discovery

Precision medicine has transformed the way we treat cancer, making it possible to match therapies to the molecular profile of each patient and revolutionize treatment approaches, leading to better outcomes. …

Continue ›››

From Electronic Noses to Agentic Drug Design: What Cancer AI Looks Like Now

Cancer AI has moved into some unusual territory. In one recent example, researchers at Linköping University reported that a 32-sensor electronic nose could distinguish ovarian cancer in blood plasma in …

Continue ›››

The €25B vs €219B Problem: Europe's Plan to Fix Biotech

Brussels is counting on new laws, sovereign AI, and billions in fresh capital to close the gap. The clock is ticking. Between 2015 and mid-2025, EU biotech startups attracted €25B …

Continue ›››

Cancer as a Data Problem: What AI Is Doing in Oncology

We track what has moved from promise to proximate execution, from AI-assisted candidate design with 2026 trial targets to agentic workflows that aim to handle multi-step oncology research tasks. Cancer …

Continue ›››

Tamarind Bio Raises $13.6M to Run 200+ AI and Simulation Models in a No-Code Platform for Bench Scientists

Tamarind Bio has secured $13.6 million in Series A financing led by Dimension Capital with participation from Y Combinator to expand its platform for coordinating and deploying AI models in …

Continue ›››